quinuclidines has been researched along with fluticasone furoate in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 21 (58.33) | 24.3611 |
| 2020's | 15 (41.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ayer, J; Lee, L; Mallett, S; Pascoe, S; Wolstenholme, A; Yang, S | 1 |
| Fath, R | 1 |
| Ali, R; Church, A; Donald, A; Kerwin, E; Siler, TM; Sousa, AR | 1 |
| Beerahee, M; Goyal, N; Lee, L; Pascoe, S; Trivedi, R; Yang, S | 1 |
| Allen, A; Brealey, N; Gupta, A; Henderson, A; Mehta, R; Renaux, J | 1 |
| Charles, S; Gillett, B; Hamilton, M; Leggett, R; Pang, C; Prime, D | 1 |
| Barnacle, H; Barnes, N; Brealey, N; Dransfield, MT; Lipson, DA; Locantore, N; Mohindra, R; Pascoe, SJ; Pavord, I | 1 |
| Lal, C; Strange, C | 1 |
| Barnacle, H; Birk, R; Brealey, N; Lipson, DA; Locantore, N; Lomas, DA; Ludwig-Sengpiel, A; Mohindra, R; Pascoe, SJ; Tabberer, M; Zhu, CQ | 1 |
| Collison, K; Kerwin, E; Lee, L; Nelsen, L; Pascoe, S; Wu, W; Yang, S | 1 |
| Birk, R; Brealey, N; Bremner, PR; Ismaila, AS; Lipson, DA; Zhu, CQ | 1 |
| Crisafulli, E; Torres, A | 1 |
| Barnhart, F; Brealey, N; Brooks, J; Criner, GJ; Day, NC; Dransfield, MT; Halpin, DMG; Han, MK; Jones, CE; Kilbride, S; Lange, P; Lipson, DA; Lomas, DA; Martinez, FJ; Pascoe, SJ; Singh, D; Tabberer, M; Wise, RA | 1 |
| Barnacle, H; Beerahee, M; Birk, R; Brealey, N; Lipson, DA; Mehta, R; Pefani, E; Zhu, CQ | 1 |
| Baker, T; Briggs, A; Driessen, M; Ismaila, AS; Naya, I; Risebrough, N; Shah, D | 1 |
| Corhay, JL | 1 |
| Fujimura, M; Hara, J; Ishii, N; Ishiura, Y; Kasahara, K; Nomura, S; Ohkura, N; Shimizu, T; Tamaki, T | 1 |
| Barnes, N; Brusselle, G; Compton, C; Criner, GJ; Dransfield, MT; Halpin, DMG; Han, MK; Hartley, B; Lange, P; Lettis, S; Lipson, DA; Lomas, DA; Martinez, FJ; Papi, A; Pascoe, S; Roche, N; Singh, D; van der Valk, RJP; Wise, R | 1 |
| Birk, R; Farrell, C; Hayes, S; Lipson, DA; Mehta, R; Okour, M | 1 |
| Criner, G; Dransfield, M; Goodall, EC; Halpin, DM; Han, MK; Ismaila, AS; Lomas, DA; Martin, A; Ndirangu, K; Risebrough, N; Schroeder, M; Shah, D | 1 |
| Clifton, CS; Gross, AS; Hashimoto, K; Ishii, T; Jones, CE; Kato, M; Kilbride, S; Lipson, DA; Nezu, Y; Tomii, K | 1 |
| Vestbo, J | 1 |
| Suissa, S | 1 |
| Dransfield, MT; Han, MK; Lipson, DA | 1 |
| Criner, G; Day, NC; Dransfield, M; Halpin, DMG; Han, MK; Jones, CE; Kaisermann, MC; Kilbride, S; Kumar, S; Lange, P; Lipson, DA; Lomas, DA; Martin, N; Martinez, FJ; Singh, D; Wise, R | 1 |
| Criner, GJ; Dransfield, MT; Halpin, DMG; Han, MK; Hanania, NA; Jones, CE; Kilbride, S; Lima, R; Lipson, DA; Lomas, DA; Mannino, DM; Martin, N; Martinez, FJ; Singh, D; Wise, RA | 1 |
| Han, MK; Lipson, DA; Martinez, FJ; Wise, R | 1 |
| Fowler, A; Lee, LA; Peachey, G; Sule, N; Yang, S | 1 |
| Boucot, IH; Caveney, S; Crim, C; Hanania, NA; Lettis, S; Mannino, DM; Patel, H; Soule, T; Tombs, L | 1 |
| Abbott, T; Balmaceda, C; Espinoza, MA; Peters, A | 1 |
| Calzetta, L; Cazzola, M; Matera, MG; Ora, J; Rogliani, P | 1 |
| Bengtson, LGS; Bogart, M; Bunner, SH; Hanania, NA; Ismaila, AS | 1 |
| Darken, P; Marshall, J; Ouwens, M; Sharma, A; Singh, B; Tansey-Dwyer, D | 1 |
| Compton, C; Haeussler, K; Halpin, DMG; Han, MK; Ismaila, AS; Malmenäs, M; Sharma, R; Vogelmeier, CF | 1 |
| Bengtson, LGS; Buysman, EK; Clark, B; Ferguson, GT; Palli, S; Sargent, A; Sethi, S; Shaikh, A | 1 |
4 review(s) available for quinuclidines and fluticasone furoate
| Article | Year |
|---|---|
Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Androstadienes; Animals; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Clinical Trials as Topic; Drug Combinations; Glucocorticoids; Humans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Recovery of Function; Research Design; Treatment Outcome | 2017 |
COPD 2017: A Year in Review.
Topics: Androstadienes; Antibodies, Monoclonal, Humanized; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Common Cold; Disease Progression; Drug Combinations; Eosinophils; Glucocorticoids; Haemophilus Infections; Humans; Interleukin-5; Moraxellaceae Infections; Muscarinic Antagonists; Noninvasive Ventilation; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Seasons; Severity of Illness Index; Tiotropium Bromide | 2018 |
Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis".
Topics: Administration, Inhalation; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Fluticasone; Humans; Network Meta-Analysis; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2023 |
A Response to: Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis".
Topics: Administration, Inhalation; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Fluticasone; Humans; Network Meta-Analysis; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2023 |
17 trial(s) available for quinuclidines and fluticasone furoate
| Article | Year |
|---|---|
A randomized, crossover study to investigate the pharmacokinetics and safety of inhaled fluticasone furoate and umeclidinium, administered separately and in combination via dry powder inhaler in healthy adult volunteers.
Topics: Administration, Inhalation; Adolescent; Adult; Androstadienes; Area Under Curve; Cross-Over Studies; Double-Blind Method; Drug Combinations; Dry Powder Inhalers; Humans; Male; Quinuclidines; Young Adult | 2015 |
Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Androstadienes; Benzyl Alcohols; Chlorobenzenes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Forced Expiratory Volume; Glucocorticoids; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines; Vital Capacity | 2015 |
Dose-response modelling of umeclidinium and fluticasone furoate/umeclidinium in asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Androstadienes; Asthma; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Forced Expiratory Volume; Humans; Muscarinic Antagonists; Nonlinear Dynamics; Quinuclidines | 2015 |
Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers.
Topics: Adult; Aged; Androstadienes; Benzyl Alcohols; Chlorobenzenes; Cross-Over Studies; Drug Combinations; Female; Healthy Volunteers; Humans; Male; Middle Aged; Quinuclidines | 2015 |
A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenotype; Practice Guidelines as Topic; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2016 |
FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.
Topics: Administration, Inhalation; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Budesonide; Chlorobenzenes; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Forced Expiratory Volume; Formoterol Fumarate; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines | 2017 |
The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.
Topics: Adult; Aged; Albuterol; Androstadienes; Asthma; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Forced Expiratory Volume; Glucocorticoids; Humans; Male; Middle Aged; Muscarinic Antagonists; Peak Expiratory Flow Rate; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2017 |
Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
Topics: Administration, Inhalation; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Female; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2018 |
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Dyspnea; Female; Glucocorticoids; Hospitalization; Humans; Intention to Treat Analysis; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines | 2018 |
Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD.
Topics: Administration, Inhalation; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Female; Humans; Male; Middle Aged; Monte Carlo Method; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines; Random Allocation | 2018 |
Effect of triple therapy in patients with asthma-COPD overlap
.
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Androstadienes; Asthma; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Cross-Over Studies; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Forced Expiratory Volume; Humans; Japan; Male; Middle Aged; Pilot Projects; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2019 |
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Therapy, Combination; Eosinophils; Female; Humans; Male; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2019 |
Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
Topics: Administration, Inhalation; Aged; Androstadienes; Anticonvulsants; Benzyl Alcohols; Bromides; Chlorobenzenes; Drug Combinations; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Predictive Value of Tests; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2020 |
The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Disease Progression; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Health Status; Humans; Japan; Lung; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Recovery of Function; Time Factors; Treatment Outcome | 2019 |
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
Topics: Aged; Androstadienes; Benzyl Alcohols; Cardiovascular Diseases; Chlorobenzenes; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2020 |
Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
Topics: Administration, Inhalation; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Combinations; Drug Monitoring; Female; Health Status Disparities; Humans; Male; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Respiratory Function Tests; Respiratory System Agents; Symptom Flare Up | 2021 |
Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN).
Topics: Administration, Inhalation; Androstadienes; Asthma; Benzyl Alcohols; Bromides; Chlorobenzenes; Double-Blind Method; Drug Combinations; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2021 |
15 other study(ies) available for quinuclidines and fluticasone furoate
| Article | Year |
|---|---|
[Once daily with a powder inhaler].
Topics: Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Dry Powder Inhalers; Forced Expiratory Volume; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2015 |
In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
Topics: Administration, Inhalation; Aerosols; Androstadienes; Asthma; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Clinical Trials as Topic; Drug Combinations; Drug Delivery Systems; Dry Powder Inhalers; Equipment Design; Humans; Inhalation; Lung; Models, Anatomic; Models, Biological; Powders; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Severity of Illness Index | 2015 |
Trelegy Ellipta--a three-drug inhaler for COPD.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Drug Interactions; Humans; Lung; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2018 |
Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective.
Topics: Adrenergic beta-2 Receptor Agonists; Androstadienes; Cost-Benefit Analysis; Delayed-Action Preparations; Disease Progression; Drug Therapy, Combination; Female; Fluticasone; Humans; Maintenance Chemotherapy; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2018 |
[IMPACT study in COPD].
Topics: Androstadienes; Benzyl Alcohols; Chlorobenzenes; Clinical Trials, Phase III as Topic; Drug Combinations; Glucocorticoids; Humans; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Randomized Controlled Trials as Topic | 2019 |
Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial.
Topics: Administration, Inhalation; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Canada; Chlorobenzenes; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Disease Progression; Drug Combinations; Drug Costs; Female; Humans; Lung; Male; Models, Economic; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quality-Adjusted Life Years; Quinuclidines; Recovery of Function; Time Factors; Treatment Outcome | 2019 |
Fixed Triple Therapy in Chronic Obstructive Pulmonary Disease and Survival. Living Better, Longer, or Both?
Topics: Androstadienes; Benzyl Alcohols; Chlorobenzenes; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2020 |
Mortality in IMPACT: Confounded by Asthma?
Topics: Androstadienes; Asthma; Benzyl Alcohols; Chlorobenzenes; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2020 |
Reply to Suissa: Mortality in IMPACT: Confounded by Asthma?
Topics: Androstadienes; Asthma; Benzyl Alcohols; Chlorobenzenes; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2020 |
Reply to López-Campos
Topics: Androstadienes; Benzyl Alcohols; Chlorobenzenes; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2021 |
Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials.
Topics: Administration, Inhalation; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Combinations; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system.
Topics: Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chile; Chlorobenzenes; Cost-Benefit Analysis; Double-Blind Method; Drug Combinations; Fluticasone; Forced Expiratory Volume; Humans; Public Health; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2022 |
A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD.
Topics: Administration, Inhalation; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Combinations; Humans; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2022 |
COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
Topics: Administration, Inhalation; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Female; Fluticasone; Humans; Male; Patient Acceptance of Health Care; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Retrospective Studies | 2023 |
Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History.
Topics: Administration, Inhalation; Adult; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Fluticasone; Humans; Patient Acceptance of Health Care; Pneumonia; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Tiotropium Bromide | 2023 |